


Cluster Headache Market: Advancements in Treatment Options and Growing Patient Demand 2031

PORTLAND, OREGON, UNITED STATES, May 25, 2023 /EINPresswire.com/ --According to the report, the <u>global</u> <u>cluster headache industry</u> generated \$356.00 million in 2021, and is estimated to reach \$522.98 million by 2031, witnessing a CAGR of 3.9% from 2022 to 2031. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.



Key Takeaways:

Definition: Cluster headaches are a type of primary headache disorder characterized by severe and recurring headaches that occur in clusters or cycles, typically lasting for weeks or months. They are considered one of the most painful types of headaches.

Prevalence and Impact: Cluster headaches are relatively rare, affecting approximately 0.1% to 0.2% of the population. They are more common in men than women. The condition can have a significant impact on the quality of life, causing intense pain, disruption of daily activities, and sleep disturbances.

Lack of Understanding: The exact cause of cluster headaches is not fully understood. However, researchers believe that abnormalities in the hypothalamus, a region of the brain, may play a role in their development. Triggers such as alcohol consumption, certain medications, and smoking have been associated with cluster headaches in some individuals.

Current Treatment Options: The treatment of cluster headaches typically involves a combination of acute attack management and preventive measures. Acute attack management often includes the use of high-flow oxygen therapy, triptans, or intranasal lidocaine. Preventive measures may involve medications such as verapamil, corticosteroids, lithium, or nerve block injections.

Emerging Therapies: Over the past few years, there have been advances in the development of new therapies for cluster headaches. One notable advancement is the use of non-invasive neuromodulation devices, such as external trigeminal nerve stimulation (eTNS) devices and transcranial magnetic stimulation (TMS), which have shown promising results in reducing the frequency and severity of cluster headache attacks.

Research and Clinical Trials: Ongoing research and clinical trials are focused on further understanding the underlying mechanisms of cluster headaches and developing more effective treatments. These studies aim to identify novel drug targets, explore the use of neuromodulation techniques, and investigate other therapeutic interventions.

Request Sample Copy of the Report: <u>https://www.alliedmarketresearch.com/request-sample/14812</u>

Market Drivers:

High Unmet Medical Need: Cluster headaches are a severely debilitating condition with limited treatment options. The intense pain and disruption caused by cluster headaches create a significant unmet medical need, driving research and development efforts to discover new and more effective treatments.

Increasing Awareness and Diagnosis: Improved awareness among healthcare professionals and the general public has led to a higher rate of diagnosis for cluster headaches. As more individuals are accurately diagnosed with cluster headaches, the demand for effective treatments and management strategies increases.

Growing Patient Population: While cluster headaches are relatively rare, the overall patient population is expanding due to factors such as population growth and increasing life expectancy. The aging population, in particular, is prone to developing cluster headaches, contributing to the growth of the market.

Market Segmentation:

Type of Treatment:

a. Acute Attack Management: This segment includes medications and therapies used to relieve the symptoms and pain during a cluster headache attack. It may include oxygen therapy, triptans, intranasal lidocaine, or other acute medications.

b. Preventive Measures: This segment focuses on medications and interventions used to prevent or reduce the frequency and severity of cluster headache attacks. It may include medications like verapamil, corticosteroids, lithium, nerve block injections, or emerging therapies like neuromodulation devices.

Distribution Channel:

a. Hospitals and Clinics: This segment includes medications and treatments provided in hospitals or specialized clinics where cluster headache patients seek medical attention.

b. Retail Pharmacies: Medications that can be obtained from retail pharmacies without a prescription fall under this segment. It may include over-the-counter pain relief medications or prescribed preventive medications.

Geography:

The cluster headache market can be segmented based on regional or global geography. Each region may have different prevalence rates, healthcare systems, treatment guidelines, and access to therapies, leading to variations in the market size and opportunities.

End Users:

a. Hospitals and Specialty Clinics: This segment includes healthcare facilities that specialize in neurology or headache disorders, where patients receive diagnosis, acute management, and preventive treatments.

b. Homecare Settings: Some cluster headache treatments, such as oxygen therapy or selfadministered medications, can be administered at home. This segment focuses on patients who receive treatment in a homecare setting.

Demographics:

a. Gender: Cluster headaches are more common in men than women. Market segmentation based on gender can help identify specific treatment needs and preferences.

b. Age: Cluster headaches can occur at any age, but they are more commonly seen in adults. Segmenting the market based on age groups may provide insights into different treatment approaches for various age demographics.

Request for Customization – <u>https://www.alliedmarketresearch.com/request-for-</u> customization/14812

Regional Growth Dynamics:

By region, North America held the major share in 2021, garnering more thantwo fifth of the global cluster headache market revenue owing to rise in prevalence of cluster headache cases and increase in number of key players offering novel therapeutics. However, Asia-Pacific would showcase the fastest CAGR of 4.8% from 2022 to 2031 owing to increase in number of headache disorders, rise in awareness campaign, and surge in investments for development of effective drugs for treating cluster headache.

Leading Market Players-

Arrotex Australia Group AstraZeneca Dr. Reddy's Laboratories Ltd. Eli Lilly and Company Fresenius SE & Co. KGaA GlaxoSmithKline plc Novartis AG Pfizer Inc Sun Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd

Buy this Premium Research Report:

https://www.alliedmarketresearch.com/purchase-enquiry/14812

VALUE PROPOSITIONS RELATED TO THE REPORT:

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Allied Market Research Allied Market Research +1 800-792-5285 email us here Visit us on social media: Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/635800586

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.